34599-42-3

Basic information

• Product Name: 6-nitrobenzindol-2(1H)-one
• Synonyms: 6-nitrobenzindol-2(1H)-one
• CAS NO: 34599-42-3
• Molecular Weight: 214.18
• Mol File: 34599-42-3.mol

Chemical Properties

• CAS DataBase Reference: 6-nitrobenzindol-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-nitrobenzindol-2(1H)-one(34599-42-3)
• EPA Substance Registry System: 6-nitrobenzindol-2(1H)-one(34599-42-3)

Safety Data

• Hazardous Substances Data: 34599-42-3(Hazardous Substances Data)

Upstream product

• 776-34-1 1-amino-4-nitronaphthalene 
• 81-84-5 1,8-Naphthalic anhydride 
• 7797-81-1 N-hydroxy-1,8-naphthalenedicarboximide 
• 2216-13-9 8-nitro-1-naphthalenecarboxylic acid 
• 129-02-2 8-amino-[1]naphthoic acid 
• 86-55-5 1-naphthalenecarboxylic acid 
• 6642-29-1 4-nitronaphthalic-1,8-anhydride 
• 28434-96-0 N-hydroxy-4-nitro-1,8-naphthalimide 
• 65300-66-5 N-(2,4-dinitrophenoxy)-4-nitronaphthalimide 
• 130-00-7 1,8-naphtholactam 

Downstream Products

• 670266-26-9 C₁₇H₁₁ClN₂O₃S 
• 442534-82-9 C₁₇H₁₀Cl₂N₂O₃S 
• 443922-67-6 C₁₇H₁₁BrN₂O₃S 
• 794552-14-0 C₁₇H₁₁FN₂O₃S 
• 794552-13-9 C₁₇H₁₁FN₂O₃S 
• 1011889-00-1 C₁₈H₁₁F₃N₂O₃S 
• 62155-54-8 DC_BD₁₆₈ 
• 397281-20-8 AG-690/15438099 
• 791787-63-8 AG-690/10776061 
• 791787-59-2 C₁₉H₁₆N₂O₅S 
• 878617-35-7 C₁₉H₁₆N₂O₅S 
• 78078-92-9 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride 
• 138384-62-0 6-{[4-(4-Hydroxy-benzenesulfonyl)-benzyl]-methyl-amino}-1H-benzo[cd]indol-2-one 
• 138384-67-5 6-{Methyl-[4-(4-nitro-benzenesulfonyl)-benzyl]-amino}-1H-benzo[cd]indol-2-one 

Relevant articles and documents

COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT

The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically acceptable salt of same, and a composition comprising same as an active ingredient, the compound according to the present invention being able to be applied as an inhibitor which can directly inhibit YAP-TEAD binding in the Hippo pathway which plays a crucial role in the occurrence of cancer.

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Preparation method of 1,8-disubstituted naphthalene series polycyclic aromatic hydrocarbon mononitration derivative

The invention provides a preparation method of 1,8-disubstituted naphthalene series polycyclic aromatic hydrocarbon mononitration derivative. The preparation method is characterized by comprising thefollowing steps: S1, dissolving 1,8-disubstituted naphthalene series polycyclic aromatic hydrocarbon and subgroup metal nitrate in an organic solvent, performing a nitration reaction under 10-60 DEG Cfor 4-10 h, and then monitoring by TLC (Thin layer chromatography) till a raw material point disappears to finish the reaction; S2, cooling a product obtained in S1 to room temperature, performing suction filtration, washing filter cake with 5-10 mL of H2O and anhydrous C2H5OH separately, and performing vacuum drying to obtain the 1,8-disubstituted naphthalene series polycyclic aromatic hydrocarbon mononitration derivative. According to the preparation method of the 1,8-disubstituted naphthalene series polycyclic aromatic hydrocarbon mononitration derivative, the product yield is 93%-96%; theproduct purity is 98%-99.5%; compared with the prior art, the preparation method has the characteristics of high product yield, high purity, low cost and simple process, and is easy to industrialize.

Preparation method of 1,8-disubstituted naphthalene mononitration derivative

The invention provides a preparation method of 1,8-disubstituted naphthalene mononitration derivative. The preparation method is characterized by comprising the following steps: S1, taking 1,8-disubstituted naphthalene as a raw material, taking main group metal nitrate as a nitration reagent, dissolving the 1,8-disubstituted naphthalene and the main group metal nitrate in an organic solvent, performing a nitration reaction under 10-60 DEG C for 4-10 h, and then monitoring by TLC (Thin layer chromatography) till a raw material point disappears to finish the reaction; S2, cooling a product obtained in step S1 to room temperature, performing suction filtration, washing filter cake with 5-10 mL of H2O and anhydrous C2H5OH separately, and performing vacuum drying to obtain the 1,8-disubstitutednaphthalene mononitration derivative. According to the preparation method of the 1,8-disubstituted naphthalene mononitration derivative, the product yield can reach 90%-95%; the product purity reaches 98.5%-99.6%; compared with the prior art, the preparation method has the characteristics of high product yield, high purity, low cost and simple process, and is easy to industrialize.

Discovery of Benzo[ cd]indol-2(1 H)-ones and Pyrrolo[4,3,2- de]quinolin-2(1 H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis

The bromodomain and extra-terminal domain (BET) family of proteins are readers which specifically recognize histone-acetylated lysine residues. Each BET bromodomain protein contains two highly homologous domains: the first bromodomain (BD1) and the second bromodomain (BD2). Pan-BET bromodomain inhibition is a potential therapy for various cancers and immune-inflammatory diseases, but only few reported inhibitors show selectivity within the BET family. Herein, we identified a series of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones with good selectivity for BET BD1. Through structure-based optimization, highly active and selective compounds are ultimately obtained. The representative compounds are the first reported inhibitors with selectivity more than 100-fold for BRD4(1) over BRD4(2). Among them, we further show that 68 (LT052) mediates BRD4/NF-κB/NLRP3 signaling inflammatory pathways with comparable protein expression and significantly improves symptoms of gout arthritis in a rat model. Therefore, selective pharmacological modulation of individual bromodomains could represent a strategy for the treatment of acute gouty arthritis.

Naphthalene imide-polyamine conjugate, preparation method and application thereof

The application provides a naphthalene imide-polyamine conjugate, a preparation method thereof and applications and belongs to the technical field of medicinal chemistry. The naphthalene imide-polyamine conjugate has the structure as shown in the specific

Identification of benzo[cd]indol-2(1H)-ones as novel Atg4B inhibitors via a structure-based virtual screening and a novel AlphaScreen assay

Targeting autophagy is a promising therapeutic strategy for cancer treatment. As a result, the identification of novel autophagy inhibitors is an emerging field of research. Herein, we report the development of a novel AlphaScreen HTS assay that combined

Cobalt-Catalyzed Direct Carbonylative Synthesis of Free (NH)-Benzo[ cd]indol-2(1 H)-ones from Naphthylamides

A cobalt-catalyzed C-H carbonylation of naphthylamides for the synthesis of benzo[cd]indol-2(1H)-one scaffolds has been developed. The reaction employs a traceless directing group and uses benzene-1,3,5-triyl triormate as the CO source, affording various free (NH)-benzo[cd]indol-2(1H)-ones in moderate to high yields (up to 88%). Using this protocol, the total synthesis of BET bromodomain inhibitors A and B was accomplished as well.

Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors

New class of FGFR1 kinase inhibitors with naphthostyril heterocycle has been identified. A series of N-phenylnaphthostyril-1-sulfonamides has been synthesized and tested in vitro. It was revealed that the most active compound N-(4-hydroxyphenyl)naphthostyril-1- sulfonamide inhibited FGFR1 with IC50 of 2 μM. In our preliminary studies, N-phenylnaphthos-tyril- 1-sulfonamides demonstrated selectivity of FGFR1 inhibition and antiproliferative activity on cancer cell line. N-phenylnaphthostyril-1-sulfonamides have a good potential for further development as anticancer agents.

Antiproliferative compounds having nitrogen-containing tricyclic ring systems and phenyl substituents

The invention relates to TS-inhibiting compounds of the formula STR1 where W is an alkylene group; D is a structure having two rings that are unsubstituted or substituted, where (i) one ring is a phenyl ring and (ii) the other ring is a phenyl ring or a 6